Sequence information
DRAVP ID DRAVPc063
Name Casirivimab
Sequence Not available
Molecular Formula Not Available
Condition/Disease COVID-19
Group Approved
Type Antibody
Description Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA.
Active sequence/Structure
External Links
DrugBank Accession Number DB15941
Pubchem ID 472422356
CHEMBL ID CHEMBL4650248
UNII J0FI6WE1QN
CAS 2415933-42-3
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT05502081 | Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients | COVID-19 | Completed | Phase 4 | Mansoura University Hospital |
| NCT04452318 | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household | COVID-19 | Completed | Phase 3 | Regeneron Pharmaceuticals |
